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ABSTRACT 
Urinary tract infections (UTI) are one of the most common infections in women and 
children worldwide. If not diagnosed and treated appropriately, it may lead to severe 
illness and long-term complications. The economic impact caused by UTI on society is 
significant. In addition, bacterial resistance to common antibiotics is spreading at a high 
rate. Recent years, the understanding of the host-pathogen interaction and activation of 
the immune response in the urinary tract has increased considerably. However, there is 
still a lack of understanding how these basic molecular events can be translated into 
clinical practise.  
 
In this thesis, the complex interaction between the uropathogenic E. coli and the urinary 
bladder and the kidney epithelium is described in the context of novel findings about 
virulence factors, immune response and complications following UTI.  
 
In the first study, we investigated the chemokine profile in the kidneys of mice with 
pyelonephritis and the impact of IL-1β by using an IL-1β knockout mouse and renal 
cell lines. We could show a robust induction of IL-8/MIP-2 and of the chemokines 
MCP-1 and RANTES, not previously associated with bacterial infection.  
 
In the second study, we described a new set of molecules involved in UTI 
pathogenicity, the metalloproteinase MMP-9 and its natural inhibitor TIMP-1. They 
increased in experimental pyelonephritis in mice and were found to be expressed by 
immune cells and resident renal cells. In children with pyelonephritis, we could link 
TIMP-1 to an increased risk of renal scarring.  
 
In the third study, we investigated the virulence factor cytotoxic necrotizing factor 
(CNF1), commonly found in uropathogenic E. coli. Increased inflammatory reaction 
could be attributed to CNF1 in vitro; however, urine from patients with UTI caused by 
CNF1 positive or negative E. coli showed no difference in inflammatory response. 
Thus, the difference seen in vitro is probably of minor importance in vivo in 
comparison to other virulence factors of the uropathogenic E. coli.  
 
In the last paper, we demonstrated that women supplemented with vitamin D had a 
stronger response of the antimicrobial peptide cathelicidin when biopsies from the 
urinary bladder were infected ex vivo. We also showed that normal urinary bladder cells 
were able to activate 25 hydroxyvitamin D3 to its functional form 1,25 
dihydroxyvitamin D3, indicating a role for locally produced vitamin D in the urinary 
bladder. In addition, bladder cells increased their cathelicidin stores after vitamin D 
treatment and exerted antibacterial properties against uropathogenic E. coli.  
 
In conclusion, this thesis presents new findings about host-microbe interaction in the 
urinary tract, the immune response and post-infectious complications of UTI. MMP-9, 
TIMP-1 and the chemokines IL-8/MIP-2, MCP-1 and RANTES were produced in the 
kidneys during pyelonephritis. IL-1β and TIMP-1 affected the severity of infection and 
renal scarring. The E. coli toxin CNF1 influenced the immune response only in vitro, 
but did not seem to influence inflammation in vivo. Finally, treatment with vitamin D 
increased the antibacterial properties of the uroepithelium by induction of the 
antimicrobial peptide cathelicidin.  
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1 INTRODUCTION 
 
The Austrian paediatrician Theodor Escherich (1857–1911) discovered the pathogen 
later to be known as Escherichia coli (E. coli) in 1885. He isolated it from urine 
samples of young girls with symptoms from the lower urinary tract, thus recognizing 
the significance of urinary tract infections (UTI) in children (Shulman, Friedmann et 
al. 2007).  Since then, much effort has been made to understand the signs and 
symptoms of UTI, and to understand the pathophysiology behind them. Nevertheless, 
diagnosing UTI is associated with considerable difficulties especially in infants and 
young children (Tullus 2011). Still it is important since extensive and sometimes 
painful radiological investigations will follow and medication for a prolonged period of 
time may be initiated. As the diagnosis is confirmed, the rapidly increasing resistance 
to urinary tract antibiotics challenges clinicians. Thus, new methods for early detection 
and treatment are paramount. Although much of this thesis has been based on 
laboratory investigations and findings, the aim has always been to link our findings to 
the patients, young or old, suffering from UTI.  
 
1.1 URINARY TRACT INFECTION 
UTI remains an important cause of serious bacterial infections especially in children 
but also in women. It accounts for significant morbidity and medical costs with an 
estimated 3 billion dollars being spent annually only in the United States (Litwin, 
Saigal et al. 2005). 
Except for early infancy, girls and women are more likely to experience a UTI than 
boys and men. Half of all women will have at least one UTI during their lifetime 
(Fihn 2003) and almost one in three women will have suffered from a UTI requiring 
treatment by the age of 24 (Foxman 2002). In Swedish children, the cumulative UTI 
incidence rate is reported to be 7.8% for girls and 1.7% for boys (Hellstrom, Hanson 
et al. 1991) by the age of 7 years which is considerably higher than the 3.3% reported 
by Winberg in 1974 (Winberg, Andersen et al. 1974).  
If the infection is confined to the urinary bladder the term cystitis is used whereas if 
involvement of the pelvis and parenchyma of the kidney is established, the term acute 
pyelonephritis is used. In children, pyelonephritis may result in chronic kidney 
disease due to tissue remodelling resulting in scar formation following the acute 
infection. In severe cases, bacteria may spread further to the blood to cause 
septicaemia. Thus, prompt diagnosis and initiation of treatment are important. New 
guidelines on paediatric UTI emphasize the need to direct resources towards early 
suspicion and diagnosis of UTI (Mori, Lakhanpaul et al. 2007).  
Due to the high incidence of UTI, it is one of the most common reasons for antibiotic 
prescription. With the high rate of recurrences, frequent courses of antibiotics in the 
same individual are not uncommon.  In addition, for children, low-dose antibiotics are 
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often prescribed as prophylaxis during extended periods of time. This combination of 
low dose and long duration favours the development of resistance to common urinary 
tract antibiotics (Williams and Craig 2011). Indeed, ever-increasing resistance rates are 
worrisome and the World Health Organization (WHO) calls antibiotic resistance one of 
the three greatest threats to human health (Wise 2011). Importantly, the efficiency of 
prophylactic antibiotics is also questioned, as their use may lead to breakthrough 
infections with resistant organisms while not actually preventing renal damage 
(Conway, Cnaan et al. 2007). Judicious use of antibiotics and development of novel 
therapeutic methods for prevention and treatment of UTI are important elements to help 
slow this progression.  
 
Until present, manipulating the immune response for use in clinical practise has proved 
difficult and has been largely a disappointment in the fight against infectious diseases 
(Dinarello 2001). On the other hand, treating inflammatory conditions like rheumatoid 
arthritis and inflammatory bowel disease with biological therapy targeting vital parts of 
the immune system has proved successful (Feldmann and Maini 2010). With more 
basic knowledge about host-pathogen interaction, new treatment strategies could be 
developed also for UTI and the complications associated to it. These would be aimed at 
reducing adverse effects of innate immunity and boosting the favourable ones, thereby 
using the innate immunity to fight infections. 
 
1.2 CLINICAL PRESENTATION 
 
The clinical symptoms of UTI are dependent on age, stage of infection, host response 
and type of bacteria causing the infection. Young infants often present with unspecific 
symptoms like fever, irritability, vomiting, lethargy, or poor feeding. As the children 
grow older, and in adults, more explicit symptoms like pain upon voiding and increased 
frequency are present in lower UTI. Upper UTI on the other hand is associated with 
flank pain and fever. Recently, a meta-analysis evaluated the diagnostic accuracy of 
UTI signs and symptoms in children. For infants, a history of previous UTI, fever more 
than 24 hours, suprapubic tenderness and absence of circumcision all increased the 
likelihood of UTI. For older children, abdominal pain and fever, back pain, new onset 
of urinary incontinence and dysuria, were most reliable (Shaikh, Morone et al. 2007). 
In a proposed algorithm for evaluating women with symptoms of UTI, a combination 
of several clinical symptoms reached a probability of UTI of 90% without laboratory 
testing (Bent, Nallamothu et al. 2002). The clinical presentations in postmenopausal 
women were more severe than in premenopausal women with more generalized 
unspecific symptoms and urinary incontinence (Arinzon, Shabat et al. 2011). 
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2 PATHOGENESIS OF UTI 
 
UTI results from bacteria entering the urinary tract from the nearby vagina and 
perineum. Since theses areas are normally heavily colonized with bacteria and the 
urethral opening is located here, the urinary tract is vulnerable to infection. The 
common pathogens causing UTI are residents of the enteric or vaginal flora. E. coli is 
by far the most common cause of UTI, causing about 80 % of infections in otherwise 
healthy women (Stamm 2002) and girls (Gaspari, Dickson et al. 2005), followed by 
Klebsiella, Enterococcus, group B streptococcus, Proteus and S. Saprophyticus. 
 
2.1 UROPATHOGENIC E. COLI 
 
E. coli is a Gram-negative rod that normally colonizes the term infant within hours after 
birth and form an important part of the normal human gut flora (Kaper, Nataro et al. 
2004) . Certain E. coli isolates can cause extraintestinal disease, hence termed ExPEC 
(Croxen and Finlay 2010). Organs targeted are diverse, for example the urinary tract, 
the central nervous system and the lungs (Kaper, Nataro et al. 2004). The mechanisms 
by which E. coli gain access to the urinary tract reflect an exceptional ability to adapt to 
an environment very different from the gut. They need to alter their metabolism (Alteri, 
Smith et al. 2009), ascend against the flow of urine and adhere to the epithelial layer. 
The E. coli that successfully invade the urinary tract harbour specific factors that 
enables them to survive. These strains of E. coli are commonly named uropathogenic E. 
coli or UPEC. 
The virulence of UPEC compared to non-pathogenic E. coli results from specific 
virulence genes in the bacterial chromosome. These vary considerably between 
different isolates and no single gene has been solely implicated in uropathogenesis 
(Wiles, Kulesus et al. 2008). Hence, UPEC is not a homogenous group but rather 
isolates of E. coli with different subsets of virulence factors enabling adherence, 
invasion and survival in the urinary tract. In line with this, there are currently no tests 
that can determine whether an E. coli strain is uropathogenic or not, unless it has been 
appropriately isolated from the urine of a patient with symptoms of UTI. 
Many bacterial factors contribute to the complex pathogenesis of UTI. In fact, 131 
UPEC-specific genes were reported, many of which may contribute to virulence 
(Lloyd, Rasko et al. 2007). Flagellae are thread-like structures that provide E. coli with 
the ability to move. It has been found to bind to TLR5 (Hayashi, Smith et al. 2001) and 
is of importance for the immune response to E. coli in UTI in mice (Andersen-Nissen, 
Hawn et al. 2007). Adhesion is a critical step for UPEC to avoid being washed out with 
the urine and the first step in a series of events leading to infection. The type-1 fimbriae 
are adhesion factors studied in great detail and are critical for adhesion and invasion of 
UPEC into bladder cells (Connell, Agace et al. 1996; Mulvey, Lopez-Boado et al. 
1998). They are equipped with a protein on the tip called FimH, which is responsible 
for the interaction with the host cell (Jones, Pinkner et al. 1995). It binds to several 
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structures on uroepithelial cells, the most important being uroplakin IA that coats the 
facet cells of the bladder (Zhou, Mo et al. 2001). They also bind to β-integrin, which 
triggers cytoskeleton rearrangement leading to bacterial internalization (Eto, Jones et al. 
2007). In renal epithelial cells, complement factor 3, which is secreted by epithelial 
cells during infection, can bind to type 1 fimbriae to form a complex that interacts with 
CD46 to promote internalization (Springall, Sheerin et al. 2001; Li, Zhou et al. 2009). 
Other fimbriae like P fimbriae are associated with kidney infection since they bind to 
glycosphingolipids on kidney epithelial cells (Eden and Leffler 1980).  
 
Interestingly, colonization of the upper urinary tract requires a tightly regulated 
interplay between virulence factors, so-called phase variation (Casadesus and Low 
2006). Flagellae are activated when the bacteria ascend towards the kidneys. To attach 
to the renal epithelial cells, P fimbriae are turned on and type 1 fimbria turned off. 
Complex interactions between P and type 1 fimbrae may be seen when P fimbriae 
attach to kidney epithelial cells at the same time as type 1 fimbriae are responsible for 
inter-bacterial binding in the renal tubule, causing tubular obstruction (Melican, 
Sandoval et al. 2011). 
 
 
 
Figure 1. Attachment to urinary bladder cells (left) and renal epithelial cells 
(right) by uropathogenic E. coli.  
Flagella provide the bacteria with mobility and may interact with the superficial 
bladder cell through TLR5. Further adhesion is provided by type 1 fimbriae binding to 
uroplakin 1A or β1-integrin, which also promote internalization into the cell. 
Complement secreted upon infection bind to the bacteria and promotes interaction with 
the bladder through CD46. In the kidney, P fimbriae of the bacteria bind to 
glycosphingolipids on the surface of renal epithelial cells. Bacterial invasion is further 
promoted by TLR4 and TLR5.  
 
Once bacteria have attached they need mechanisms to survive in the new environment. 
Since iron is an essential nutrient for UPEC viability and the urinary tract is a low-
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iron environment, they exhibit multiple mechanisms for iron extraction. In fact, a 
large part of the UPEC genome is devoted to iron scavenging genes. For UPECs to 
gain access to the host tissue cytotoxic proteins are produced. One example is alpha-
hemolysin which is a well characterized virulence factor frequently expressed by E. 
coli causing UTI (Smith, Rasmussen et al. 2008). In the early stage of acute 
pyelonephritis, when bacteria attach to the kidney epithelial cells, alpha hemolysin 
induces calcium oscillations intracellularly which activates the proinflammatory 
cytokines IL-6 and IL-8 (Uhlen, Laestadius et al. 2000) and in the bladder, sloughing of 
the uroepithelium and bladder haemorrhage is initiated (Smith, Rasmussen et al. 2008).  
 
Another virulence factor that causes cytoskeletal rearrangements is cytotoxic 
necrotizing factor 1 (CNF1). CNF1 is a member of the Rho family of GTPase 
activating toxins and is often genetically linked to alpha-hemolysin (Blanco, Alonso et 
al. 1990). It can induce an inflammatory reaction and apoptosis in uroepithelial cells 
(Mills, Meysick et al. 2000). Animal studies however, have shown conflicting results 
from different research groups regarding its role in vivo. Bacteria can also produce 
biofilm to protect it from immune defense mechanisms. Curli fimbriae and cellulose 
are key components in biofilm formation (Kai-Larsen, Luthje et al. 2010).  
 	  
Table 1. Some common virulence factors to UPEC and their major functions.  
 
Virulence factor Major function 
Flagella Ascension of E. coli in the urinary tract 
Type 1 fimbriae Adhesion to bladder epithelial cells, 
interbacterial adhesion 
P fimbriae Adhesion to kidney epithelial cells 
Dr fimbriae Cell invasion  
F1C fimbriae  Unknown  
Cytotoxic Necrotizing Factor 1 Adhesion, invasion, apoptosis of host cells 
Hemolysin Invasion, tissue damage 
Secreted autotransporter toxin  Tissue damage  
LPS Immune response activator 
Curli fimbria  Adhesion, biofilm formation, invasion 
Cellulose Biofilm formation 
Iron and zinc acquisition (several)  Nutrition 
Capsule Resistance to phagocytosis 
 
Bacteria also carry pathogen associated molecular patterns (PAMPs) that are structures 
on the bacterial surface that the host cells can recognize and mount an appropriate 
response against. Lipopolysaccharide (LPS) is the classic gram negative PAMP and is 
situated on the outer membrane. The contribution of LPS to UTI pathogenesis is 
debated. Unlike myeloid cells that respond promptly to LPS, uroepithelial cells respond 
weakly. One reason is the lack of membrane-associated CD14 which is an important 
LPS receptor in complex with toll-like receptor 4 (TLR4), which has been identified in 
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biopsies from the epithelium of the entire urinary tract (Samuelsson, Hang et al. 2004). 
The capsule of the UPEC is important for protection against the host response for 
example complement-mediated killing (Buckles, Wang et al. 2009). In the kidney, 
there are also ways for non-cytolytic bacteria to enter the kidney epithelial cells 
however. While cytolytic UPEC like the prototypic strain CFT073 used in this thesis 
can invade the renal epithelium to reach the underlying tissue, non-cytolytic UPEC use 
a lipid-raft mediated transport in order to translocate through the epithelium (Chassin, 
Vimont et al. 2008). 
 
Taken together, the virulence factors of UPEC are diverse and complex and no specific 
combination of presence or absence of virulence factor genes can serve as a marker to 
predict recurrent UTIs. It seems however as if E. coli causing recurrent UTI have more 
virulence factor genes than E. coli causing sporadic UTI (Ejrnaes, Stegger et al. 2011).  
 
 
2.2 HOST FACTORS 
 
Apart from the distal one-third of the urethra, where a mix of commensal bacteria can 
be found, the urinary tract is normally sterile. This is in spite of the close proximity to 
the gastrointestinal tract. Thus, there must be ways for the urinary tract epithelium to 
efficiently defend itself from invading pathogens. The first-line defence against 
microorganisms in the urinary tract consists of the mechanical properties of the highly 
specialized transitional uroepithelium, the unidirectional flow of urine, anatomical 
structures like the flap-valves of the vesicoureteral junction and biochemical factors 
like neutralizing peptides for example mucin and Tamm Horsfall protein, 
immunoglobulin and antimicrobial peptides (Chromek and Brauner 2008).  Since white 
blood cells are not normally found in the urine, the sterility is rather a result of action of 
the epithelial cell layer. Recent research from our group suggests that the fast innate 
immune response of the epithelial lining is highly important (Chromek and Brauner 
2008; Hertting, Holm et al. 2010). Although a combination of mechanical and 
epithelial factors is probably involved, little focus has been attributed to the biological 
defence of the uroepithelium.  
 
Importantly, the outcome of the action of virulence factors mentioned above may be 
different in the lower and upper urinary tract. One example is apoptosis. Several 
virulence factors of UPEC seem to have pro-apoptotic properties, including type 1 
fimbriae (Klumpp, Weiser et al. 2001), alpha-hemolysin (Chen, Tofighi et al. 2006) 
and CNF1 (Mills, Meysick et al. 2000). Apoptosis is probably a beneficial process for 
the host in early lower UTI. It results in exfoliation of the superficial cells of the multi-
layered epithelium and thus also eradication of the bacteria attached to and invaded into 
the cells. In the kidney however, where the epithelium is single-layered and close to the 
underlying kidney tissue and blood vessels, apoptosis is more likely to be part of a 
deleterious circle of tubular atrophy, cytolytic events and renal scarring (Serlachius, 
Sundelin et al. 1997; Yang, Johnson et al. 2001). For the bacteria however, it provides 
access to the kidney tissue. 
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2.2.1 Mechanical properties 
 
2.2.1.1 Urine flow 
The urine flow contributes to the sterility of the urine by making it difficult for 
bacteria to enter the urinary bladder. If they enter and attach to the uroepithelium, the 
flow of urine flushes the exfoliated cells out and thus also clearing the bacteria bound 
or invaded into them.  As a result, voiding dysfunction or residual urine in the bladder 
lead to reduced flow of urine and in turn risk of bacterial growth. Also, the flap-like 
valves of the vesicoureteral junction prevent retrograde flow of urine into the ureters 
and kidneys. As mentioned, children with vesicoureteral reflux may therefore be of 
greater risk of infection. 
2.2.1.2 Uroepithelium 
The uroepithelium itself is interesting because it is unique to the body by being 
flexible to allow filling and emptying of the bladder and at the same time 
impermeable to fluid and able to cope with the varying pH, osmolality and toxicity, 
for example high ammonium concentration (Apodaca 2004). It has a distinct 
composition of different layers of cells with the umbrella or facet cells lining the 
lumen. They are multinuclear, large cells with uroplakin facing the urine. Uroplakins 
are proteins contributing to the impermeability of the epithelium but can also act as a 
receptor for type 1 fimbriae on the uropathogenic E. coli (Wu, Sun et al. 1996).  
2.2.2 Innate immune response 
The innate immune system is our first line of defence against invading organisms and 
does not depend on prior exposure to a specific pathogen (Chaplin 2010). It must 
therefore be rapid and cannot rely on recruitment of immune cells or the production 
of antibodies. The uroepithelial cells are the first to encounter invading UPECs. 
Consequently, they are equipped with receptors that sense microbes and initiate a 
response in order to limit the infection process. However, the host must be able to 
distinguish between pathogenic and non-pathogenic bacteria in order to avoid 
constant activation of the immune system. LPS is a classic PAMP but is present in 
both non-pathogenic and pathogenic E. coli. It has therefore been proposed that the 
lack of the LPS-receptor CD14 on uroepithelial cells prevents activation by non-
pathogenic E. coli whereas TLR4 together with specific co-receptors and several 
adaptor proteins activates the cells (Fischer, Yamamoto et al. 2006). TLR4 
downstream signalling eventually results in the production of proinflammatory 
cytokines (Fischer, Ellstrom et al. 2007). Type 1 fimbriae or P fimbriae can activate 
the innate immune response through interaction with TLR4 by their respective 
receptors whereas commensals, which normally lack P fimbriae, do not. 
Consequently, children who developed UTI have increased tendency to carry E. coli 
strains with P fimbriae in their faecal flora and these strains also cause their infection 
(Plos, Connell et al. 1995). 
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If UPEC come in contact with the epithelium, within minutes, the antimicrobial 
peptide cathelicidin is secreted (Chromek, Slamova et al. 2006) and acts on the 
bacteria. Within hours, cytokines and chemokines are produced (Hertting, Khalil et 
al. 2003) and their signalling will start to recruit professional immune cells to the site 
of infection (Connell, Agace et al. 1996). The bacteria on the other hand, will try to 
circumvent the immune defence in different ways. One is to enter the cell cytoplasm 
and form intracellular bacterial communities (IBCs) in order to “hide” from the 
immune response (Hunstad and Justice 2010); another is to down regulate the 
immune response with different modes of signalling (Hunstad, Justice et al. 2005). 
Depending on the number of bacteria, the virulence factors they carry and the host 
status, the bacteria will either persist in the urinary tract or be eliminated and washed 
out with the urine.    
2.2.3 Cytokines and chemokines in UTI 
 
If this first line of defence against pathogens entering the urinary tract fails, an 
inflammatory response is initiated. Attachment to the bladder uroepithelial cells by 
bacterial fimbriae allows for close contact between host and pathogen. Transmembrane 
signalling through TLRs leads to the production of inflammatory mediators such as 
chemokines with subsequent recruitment of professional immune cells to the infectious 
focus. Chemokines are divided into different groups depending on cysteine 
arrangement, hence named CC, CXC, C or CX3C chemokines. Specifically, the CXC-
chemokine IL-8 is needed for neutrophil recruitment and activation in the urinary 
tract (Agace, Hedges et al. 1993). Now, a second wave of neutrophil-derived 
antimicrobial peptides can act to eliminate invading bacteria (Chromek, Slamova et al. 
2006). Other toxic components, like lysozyme, elastase and myeloperoxidase are also 
released by the neutrophils, and bacteria are cleared by phagocytosis. Neutrophils are 
crucial for UPEC clearance in UTI, as shown by depletion of neutrophils in a UTI 
model, resulting in impaired bacterial clearance (Haraoka, Hang et al. 1999). The 
neutrophils may however also cause unwanted effects for the host such as tissue 
destruction (Jahnukainen, Chen et al. 2005).  
 
When the inflammatory response subsides, bacteria may still be left in the bladder 
epithelium. Bacteria that form IBCs can escape the different steps in host defence 
(Anderson, Palermo et al. 2003) and treatment with antibiotics will be less efficient 
because of poor antibiotic penetration into the IBCs. From the IBC, bacteria can be 
expelled from the cells by a TLR4 mediated mechanism (Song, Bishop et al. 2009) or 
in mature IBCs, bacteria form filamentous structures, then detach from the cell to 
colonize adjacent cells (Justice, Hunstad et al. 2006). The cells may also be exfoliated 
allowing the underlying immature cells to be exposed to further UPEC invasion. Here, 
they can turn into quiescent intracellular reservoirs (QIRs) for weeks, only to re-emerge 
to cause recurrent infections (Mysorekar and Hultgren 2006).  
If the bacteria ascend further in the urinary tract, pyelonephritis may develop. In the 
kidney bacteria may cause tissue damage and reach the blood circulation, causing 
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septicaemia, commonly called urosepsis. This increases the mortality from 0.3% in 
pyelonephritis to 7.5-30% in urosepsis (Foxman, Klemstine et al. 2003; Brown, Ki et 
al. 2005). Furthermore, destruction of the kidney tissue may cause renal fibrosis, 
scarring, which in the end may affect the renal function in a deleterious way. Unlike 
the process of P fimbriae mediated attachment, the process of bacteria entering the 
kidney tissue is less well understood but seems to involve a TLR4-facilitated lipid 
raft mediated translocation across renal collecting duct cells (Chassin, Goujon et al. 
2006). Collecting duct cells are the primary site of UPEC adherence and have 
abundant TLR4 expression. For clearance of bacteria from kidney tissue, chemokines 
and the chemokine receptor CXCR1 are pivotal. Lack of CXCR1 receptor in mice 
leads to neutrophil entrapment and renal scaring (Hang, Frendeus et al. 2000) and 
may possibly have a human counterpart in patients susceptible to pyelonephritis 
where low CXCR1 expression was found (Frendeus, Godaly et al. 2000).  
2.2.4 Matrix metalloproteinases 
 
Successful eradication of uropathogenic E. coli by the host requires initiation of 
chemokine release and influx of immune cells. However there must also be a 
resolution of inflammation and finally remodelling of the extracellular matrix (ECM). 
Matrix metalloproteinases (MMPs) are zinc-containing enzymes and, as a group, with 
the ability to degrade all components of the ECM (Sternlicht and Werb 2001). MMPs 
are not expressed in healthy tissue but can be detected in any remodelling process in 
virtually all cells in the body (Parks, Lopez-Boado et al. 2001). Different MMPs have 
different substrates however and they are the only known enzymes to be able to 
digest collagen. They are tightly regulated on a transcriptional level as well as on the 
activating level (Hadler-Olsen, Fadnes et al. 2011). They are produced as pro-forms 
and cleavage to its active form is carried out by other MMPs and other proteinases. 
MMPs are additionally regulated by the tissue inhibitors of metalloproteinases 
(TIMPs), which bind to the catalytic site of MMPs, thereby inhibiting uncontrolled 
digestion of ECM components (Bode, Fernandez-Catalan et al. 1999). MMP-2 and 
MMP-9 are so called gelatinases with gelatin-binding domains that enable enhanced 
interaction with collagen (Parks, Wilson et al. 2004). They are typically anchored to 
the cell membrane, thus achieving high enzymatic activity locally. Today, MMP 
functions have expanded beyond ECM remodelling to include multiple steps of 
immune activation. In the early response, MMPs activate antimicrobial peptides and 
chemokines. For example, MMPs may cleave cytokines or chemokines either to 
augment or to inhibit their functional activity (Parks, Wilson et al. 2004). MMPs are 
involved in the local tissue damage that facilitates migration of leukocytes towards a 
chemokine gradient. In the brain, they are produced by leucocytes in order to break 
down the blood–brain barrier (Yong, Power et al. 2001) and cause vascular leakage in 
sepsis (Tressel, Kaneider et al. 2011). In kidney, MMP-9 has been linked to fibrosis 
in obstructive nephropathy in mice (Wang, Zhou et al. 2010). 
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2.2.5 Antimicrobial peptides 
 
In 1981, Hans Boman and co-workers isolated the antimicrobial peptide (AMP) 
cecropin from the moth cecropia (Steiner, Hultmark et al. 1981). Today, more than 
1000 peptides with antimicrobial properties have been identified. AMPs are peptides 
that participate in the early innate immune response. They are exceptionally well 
conserved evolutionary, which imply that they have been of crucial importance for 
survival in plants, insects and mammals. In insects, systemic levels of AMPs are very 
high whereas in mammals they are barely detectable in the resting state but induction is 
seen upon microbial stimulation. AMPs are positively charged peptides with broad-
spectrum antimicrobial activity; bacteria, viruses, parasites and fungus are all potential 
targets. They are multifunctional with chemotactic, angiogenetic and wound healing 
properties (Lai and Gallo 2009). In humans, defensins and cathelicidin are the most 
important. They are produced as precursor proteins, which then are activated to form 
the active peptides. The antibacterial activity is targeted at the bacterial membrane and 
involves peptide-pathogen interaction by electrostatic attraction between the positively 
charged peptides and the negatively charged bacteria. This leads to membrane damage 
through a number of complex mechanisms (Toke 2005).  
 
2.2.5.1 Defensins 
 
In the urinary tract, human beta defensin-1 (HBD-1) is found in the distal nephron of 
human kidney and is thought to be the primary source of urine HBD-1. In contrast to 
cathelicidin, defensins seem to be expressed constitutively to a higher degree and reach 
much higher concentrations in the urine. Interestingly, it was shown that pregnant 
women have higher HBD-1 levels in the urine than both non-pregnant women and men 
(Valore, Park et al. 1998) suggesting hormonal regulation of defensins and an increased 
need for local protection during pregnancy. In pyelonephritic kidneys both HBD-1 and 
HDB-2 have been found (Lehmann, Retz et al. 2002) and in cultured human kidney 
cells, HDB-2 was produced in response to synthetic TLR2, TLR3, TLR4, TLR7, 
NOD1 and NOD2 agonists (Uehara, Fujimoto et al. 2007).  
 
2.2.5.2 Cathelicidin 
 
Only one cathelicidin is known in man. It is encoded by the CAMP gene and is 
expressed as a precursor protein hCAP18. This protein is later cleaved to LL37, a 
peptide of 37 amino acids with potent antimicrobial activity. It was initially shown that 
hCAP18 cleavage was performed by proteinase 3 present in neutrophils (Sorensen, 
Follin et al. 2001). The precursor hCAP18 can also be processed to peptides other 
than LL37, which also display antimicrobial activity (Murakami, Lopez-Garcia et al. 
2004). In neutrophils, LL37 is stored in granules but the storage and cleavage in 
epithelial cells is less well understood. In this text we use the word cathelicidin to 
describe hCAP18 and LL37 together. Cathelicidin is expressed and secreted in 
response to hostile microbial stimuli in both immune cells and epithelial cells. Apart 
from its well-recognized antibacterial effects, cathelicidin has additional 
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immunoregulating properties. It can neutralize LPS, activate epithelial cells and it has 
chemotactic activity towards neutrophils, monocytes, T cells (De, Chen et al. 2000), 
mast cells (Niyonsaba, Iwabuchi et al. 2002) and eosinophils (Tjabringa, Ninaber et al. 
2006). The chemotactic activity is achieved through interaction with formyl peptide 
receptor-like 1 (FPRL1) (De, Chen et al. 2000). Recently, cathelicidin was also 
reported to inhibit biofilm formation by interacting with the curli fimbria of 
uropathogenic E. coli (Kai-Larsen, Luthje et al. 2010).	  
In urinary tract cells, cathelicidin seems to react very rapidly in response to bacterial 
stimuli (Chromek, Slamova et al. 2006). This probably stops bacterial division, which 
provides an efficient way for the host to halt an impending bacterial infection at an 
early stage (Chromek and Brauner 2008). This is of importance since uropathogenic 
E. coli replicates rapidly in the urine during UTI. In uropathogenic E. coli taken 
directly from the urine of women with UTI, the most highly expressed genes were 
those encoding ribosomal proteins (Hagan, Lloyd et al. 2010), which are known to 
increase proportionally to growth rate (Gausing 1977).  
The mechanism of activation of cathelicidin seems to differ between organ and cell 
type. In contrast to defensins, cathelicidin seems only partly to be dependent on TLR 
or cytokine signalling. Rather, histone acetylation and vitamin D signalling seems 
important. Interestingly, butyric acid can increase histone acetylation. In a model of 
Shigella enteritis in rabbit, oral butyrate treatment reduced clinical illness, 
inflammation and bacterial load (White 2008).  
2.2.5.3 Vitamin D 
 
Vitamin D is a steroid hormone that has multiple effects on human health, the most 
important being the regulation of calcium homeostasis. Consequently, hypercalcaemia 
is the most important side effect of vitamin D treatment. Vitamin D is produced from 
precursors originating in the skin under the influence of UVB light or from digestion of 
animal products, mainly fatty fish or fortified dairy products (Ross 2011). Since 
activation in the skin is dependent on the intensity of UVB light, people in the Nordic 
hemisphere will produce little vitamin D during winter months but also protection from 
the sun by clothing or sunscreen in summertime will reduce vitamin D activation.  Two 
enzymatic steps activate Vitamin D before it can bind with high affinity to the 
vitamin D receptor (VDR). Activation normally starts in the skin, where UVB 
radiation converts 7-dehydrocholesterol to cholecalciferol. In the next step, the 
hepatic 25-hydroxylase CYP27A1 produces 25-hydroxycholecalciferol (25D3), which 
relocates to the circulation, bound to vitamin D binding protein (DBP). The last step 
is when the renal 1α-hydroxylase CYP27B1 converts 25D3 to the active 1,25D3 or 
calcitriol. 1,25D3 binds to VDR in target cells, until the 24-hydroxylase (CYP24A1) 
inactivates it (Prosser and Jones 2004). 	  
In recent years, the presence of CYP27B1 in peripheral tissue other than the kidney has 
led to a completely new way of looking at vitamin D metabolism since it allows local 
vitamin D activation in response to different stimuli to take place (Zehnder, Bland et al. 
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2001). There seems to be only one type of vitamin D receptor in humans and this 
receptor mediates all vitamin D effects. The number of VDR binding sites on the 
genome is cell type-specific however, making different cell types or tissue respond 
differently to vitamin D (Pike, Meyer et al. 2011). 
  
The connection between vitamin D and infectious diseases is as much medical history 
as it is modern molecular medicine. The notion that being outdoor was beneficial for 
patients with infectious diseases dates back to the late 1800s when nobody knew why, 
but tuberculosis patients sent to rest in sanatoria at sunny places and with nourishing 
diet often experienced some degree of remission (Campbell 2005). Later, the 
connection between UVB light from the sun and the production of vitamin D in the 
skin became evident and in 1983 the presence of vitamin D receptors in human 
leucocytes indicated that non-classical vitamin D activity could also include the 
immune system (Provvedini, Tsoukas et al. 1983).  
 
The discovery that vitamin D directly induces production of the antimicrobial peptide 
cathelicidin (Wang, Nestel et al. 2004; Gombart, Borregaard et al. 2005) further 
strengthen the link between vitamin D and innate immunity. In 2006, the mechanism 
behind this upregulation in immune cells was demonstrated. It included TLR activation 
of human macrophages, which increased expression of the VDR and the converting 
enzyme CYP27B1 genes. This in turn led to induction of cathelicidin and killing of 
intracellular M. tuberculosis (Liu, Stenger et al. 2006). As a consequence, many 
studies on vitamin D and its effect on innate immunity were initiated. In fact, in the 
2007 Time magazine list of the top medical breakthroughs of the year, the benefits of 
vitamin D was number 10 (Guthrie 2007). The link between vitamin D and cathelicidin 
is possible because of a vitamin D responsive element (VDRE) located upstream in the 
cathelicidin gene (CAMP) promoter (Wang, Nestel et al. 2004). The VDRE in the 
CAMP gene originated in the lineage leading to humans, apes, old world monkey and 
new world monkeys and it has been estimated that this happened about 50 million years 
ago (Gombart, Saito et al. 2009). As a result, rodent models of infection cannot be used 
for studying vitamin D induction of CAMP.  
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3 RISK FACTORS  
 
General risk factors of UTI and especially recurrences are for example urinary catheter 
carriage or poorly controlled diabetes mellitus (Muller, Gorter et al. 2005). In men 
presenting with UTI, which will not be covered here, obstruction of the lower urinary 
tract should always be suspected since the most common cause, next to urolithiasis, is 
prostate hyperplasia (Heyns 2011).  
 
3.1 CHILDREN 
 
Specific risk factors in children include infrequent voiding, poor fluid intake and 
functional stool retention, which were more frequent in girls with recurrent urinary 
tract infections than in control girls (Stauffer, van der Weg et al. 2004). If the urinary 
bladder is not emptied sufficiently, as is the case in neurogenic bladder and other 
conditions of dysregulated bladder emptying, the residual urine may be colonized with 
bacteria. In a Swedish study of adolescents with myelomeningocele, 15% had recurrent 
UTI but only 1.7% had decreased renal function (Olsson, Dahl et al. 2007). In children, 
congenital hydronephrosis, vesicoureteral reflux, ureteropelvic junction obstruction or 
ureterovesical junction obstruction are all anatomic anomalies associated with UTI 
(Figure 3). These structural risk factors highlight the importance of regular emptying 
of the bladder to avoid bacteria to multiply and gain access to the urinary tract.  In 
other words, the urinary tract depends partly on the unidirectional flow of urine for its 
sterility to be maintained. The link between anatomical anomalies in the urinary tract 
and its role in UTI and renal scarring is under debate. For example, combined surgical 
and antibiotic treatment for vesicoureteral reflux caused a 57% reduction in febrile 
UTIs by five years of age but did not decrease the risk of progressive renal damage 
(Nagler, Williams et al. 2011) 
 
 
 
Figure 2. Anatomical 
abnormalities may predispose 
to UTI.                 
A. Posterior urethral valve    
B. Vesicoureteral valves     
C. Ureteropelvic obstruction 
Left-sided vesicoureteral reflux 
is seen. 
 
Image courtesy of the National Institute 
of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health. 
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3.2 WOMEN 
 
Known risk factors in pre-menopausal women include sexual intercourse and 
pregnancy (Foxman 2002). Asymptomatic bacteriuria occurs in 2% to 10% of 
pregnancies and, if untreated, around 30% of these women will develop acute 
pyelonephritis (Smaill and Vazquez 2007). UTI in pregnancy is correlated to intra-
uterine growth restriction, pre-eclampsia, caesarean sections and pre-term deliveries 
(Mazor-Dray, Levy et al. 2009). Using certain types of birth control may also increase 
the risk for UTI (Foxman and Chi 1990). After menopause, UTI may become more 
common because of lower estrogen levels, which may cause mucosal vulnerability 
and influence the production of the defensin HBD-2 in the vagina (Han, Kim et al. 
2010). In contrast to children and men, anatomical abnormalities are rarely found in 
women, even if they have recurrent infections (Finer and Landau 2004).  
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4 COMPLICATIONS 
 
Normally, UTIs treated accurately resolve quickly and are not associated with severe 
complications. In a minority, however, UTI may cause severe infection and long-term 
disabilities. Infants younger than 3 months are at increased risk of bacteraemia 
(Richardson and Lakhanpaul 2007) and pregnant women are as mentioned at high risk 
of UTI. The most common complications and the ones covered in this thesis are 
recurrent infections and renal scarring following UTI in children.  
 
4.1 RECURRENT URINARY TRACT INFECTIONS 
 
25% of women will have a recurrent UTI following their primary infection although 
they do not have obvious urinary tract anatomical abnormalities (Finer and Landau 
2004). These recurrences are often caused by the same bacterial strain, suggesting 
incomplete resolution of the primary infection rather than a new infection (Brauner, 
Jacobson et al. 1992; Russo, Stapleton et al. 1995). The new findings regarding the 
intracellular life-style of UPECs have introduced new aspects of the pathology behind 
recurrent UTIs. This may explain why some patients develop UTI very frequently 
despite antibiotic treatment.  
 
4.2 RENAL SCARING 
 
If the host response fails, bacteria may ascend to the upper urinary tract and cause 
pyelonephritis. The inflammation caused by the infection can lead to renal scarring, 
especially in children. Renal scaring is a process involving a number of actors. A 
crucial event is the influx of neutrophils. As a consequence, granulocytic cytotoxic 
products including lysozyme, elastase and myeloperoxidase are released and oxidative 
bursts occur (Heinzelmann, Mercer-Jones et al. 1999). These processes, aimed at 
killing and removing the pathogens may paradoxically be deleterious to the host with 
tissue destruction and fibrosis to follow (Jahnukainen, Chen et al. 2005). As a result of 
more widely available antenatal ultrasound imaging, scarring of the kidney has also 
been attributed to congenital abnormalities (Wennerstrom, Hansson et al. 2000).  
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5 AIMS OF THE THESIS 
 
The overall aim of this thesis was to provide a greater insight to the host-pathogen 
interaction in urinary tract infection. This is important for several reasons. New 
diagnostic techniques are needed for early recognition of UTI, for distinguishing 
patients with upper or lower UTI and for risk assessment for recurrent UTIs or chronic 
kidney damage following pyelonephritis. Data about the pathophysiological basis of 
UTI are also needed to understand the role of the innate immunity in order to develop 
new treatments.  
 
Specific aims for the included papers were: 
 
 
I. To study the effect of E. coli and IL-1β on the expression of IL-8/MIP-2, 
MCP-1 and RANTES in an experimental mouse model of pyelonephritis. 
 
II. To investigate MMP9 and TIMP-1 induction and its relation to renal 
scarring in children with pyelonephritis. 
 
III. To study the contribution of the E. coli virulence factor CNF1 to the 
immune response in the urinary tract in children and adults with urinary 
tract infection.  
 
IV. To investigate if vitamin D treatment can induce the antimicrobial 
peptide cathelicidin in the urinary tract of postmenopausal women. 
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6 MATERIALS AND METHODS 
 
6.1 CLINICAL STUDIES 
 
Three of the papers presented in this thesis include clinical material from human 
subjects. Paper II and III involve children with UTI, paper III also adults with UTI and 
paper IV includes adult volunteers. All studies were approved by the local ethics 
committees as described in each separate publication. All episodes of UTI were caused 
by E. coli and verified by a positive bacterial culture with bacterial growth of > 105 
CFU/mL in the urine. For acute pyelonephritis, additional criteria of rectal temperature 
> 38° C, CRP > 20 mg/L or ESR > 20 mm/hr were used. In paper IV, women post 
menopause (at least 12 months since a menstrual period), were included. Exclusion 
criteria were urological malformations or other kidney diseases, UTI or recent 
supplementation with vitamin D. Oral supplementation with 2000 IU of 25D3 was 
given daily for 12 weeks. Before treatment started, blood was collected for analyses 
and urinary bladder biopsies were taken for in vitro infection. The study is 
schematically outlined in figure 3. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schedule for vitamin D supplementation study presented in paper IV. 
Bladder biopsies were taken from healthy postmenopausal women and 
supplementation with 2000 IU of vitamin D3 daily was initiated. Blood sampling was 
performed at baseline, at six weeks and at twelve weeks when follow-up biopsies also 
were taken. 
 
 
6.1.1 DMSA scan 
 
DMSA scan is performed by injecting radio labelled dimercaptosuccinic acid (DMSA) 
intravenously and then visualising kidney uptake using a gamma camera. In paper II, 
data from children with DMSA scan performed within 10 days after acute infection and 
at 1-year follow-up were used. DMSA scan is a sensitive method of detecting acute 
pyelonephritis (Jaksic, Bogdanovic et al. 2011) and renal uptake is normally a good 
way of measuring renal function (Quinn and Elder 1991). It is also the preferred 
method of assessing renal scars in the kidneys (Moorthy, Wheat et al. 2004). In order to 
S-25D3 
S-Cathelicidin 
Cystoscopy 
Bladder biopsy 2 
Cystoscopy 
Bladder biopsy 1 
 
Start 
25D3 
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IU/d 
6 weeks 12 weeks 
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S-Cathelicidin 
S-25D3 
S-Cathelicidin 
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standardize the interpretation of the DMSA scans, a score has been calculated by 
determining uptake defects in the kidneys (Tullus, Fituri et al. 1994).  
 
6.1.2 Serum analyses 
 
In papers and II, III and IV, serum analyses of CRP, ESR, creatinine, calcium, 
glucose, parathyroid hormone and phosphate were analysed using routine hospital 
methods. Serum cathelicidin in study IV was analysed with ELISA. An antibody-
based chemiluminescence assay was used for total serum 25D3 analyses. 
 
6.2 MOUSE MODEL OF UTI 
 
An experimental model of acute pyelonephritis in mouse was used in paper I and II. 
Bki NMRI outbred mice or C5BL/6 inbred mice were used between 8 and 10 weeks of 
age. To establish UTI, a thin catheter was introduced into the urethral meatus under 
general anaesthesia (Hung, Dodson et al. 2009) followed by inoculation of 50 µl of 
either E. coli CFT073 (109 CFU/mL) or normal saline in control mice. In order to avoid 
immediate voiding, the meatus was obstructed for 6 hours with collodium. In paper I, 
IL-1β deficient mice on C5BL/6 background was used in addition to its wild type 
counterpart. It was created by gene targeting in embryonic stem cells to introduce an 
IL-1β null allele. The phenotype is healthy and fertile but resistant to fever (Zheng, 
Fletcher et al. 1995). At 0, 24, 48 hours or 6 days, mice were sacrificed and organs 
were aseptically collected for further analyses. Homogenized kidneys were used for 
bacterial count and protein measurement and whole kidneys were prepared for 
immunohistochemistry or in situ hybridization. 
 
6.3 IN VITRO EXPERIMENTS 
 
6.3.1 Bacteria 
 
The prototypic uropathogenic E. coli CFT073 was used in paper I, II and IV. It was 
isolated from the urine and blood of a patient with pyelonephritis (Mobley, Green et al. 
1990). CFT073 has been fully sequenced and encodes several fimbrial genes, 
including type 1, P, F1C, Dr, Auf, S fimbriae (Welch, Burland et al. 2002). It has 
been widely used to induce urinary tract infection in mice (Johnson, Russell et al. 1993; 
Mobley, Jarvis et al. 1993; Cirl, Wieser et al. 2008; Cirl, Wieser et al. 2008).  
In paper III, uropathogenic E. coli CP9 were used. It is derived from a CNF1 positive 
human urosepsis isolate. CP9cnf1 carries an in-frame deletion mutation in the CNF1 
gene and CP9lacZ is the wild-type counterpart. In paper IV, a GFP-labelled CFT073 was 
used to detect CFT073 intracellularly (Mansson, Melican et al. 2007).  
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6.3.1.1 Pulse-field gel electrophoresis 
 
Pulse-field gel electrophoresis (PFGE) is used for determining genetic similarity 
between different bacterial strains. In paper III, we used PFGE to determine if UTIs in 
children with repeated infections were caused by the same bacterial strain. Colonies 
from overnight cultures were washed in water and Tris-EDTA buffer. Chromosomal 
DNA was prepared in agarose plugs and digested with restriction enzymes. Gel 
electrophoreses was then performed and a photo was taken. Strains with the identical 
PFGE profile were defined as representing the same strain. 
 
6.3.1.2 Studies on multinucleation and bacterial adhesion 
  
In paper III, the presence of CNF1 in clinical strains was determined by investigating 
multinucleation in HeLa cells (Island, Cui et al. 1998). Sonicated bacterial strains were 
added to confluent HeLa cells for 24 hours. Cells were fixed, stained with Giemsa 
reagent and assessed under light microscope. For attachment assay in paper III, cells 
were pre-stimulated with sonicated bacteria and then infected with live CP9cnf1 or 
CP9lacZ bacteria for 30 minutes. Cells were washed and then lysed with triton X-100 
and plated on blood agar plates overnight for bacterial CFU counting. 
 
 
6.3.2 Cells 
 
Different urinary tract and monocytic cell lines as well as normal bladder and 
mesangial cells were used. T24 and 5637 cells are derived from patients with bladder 
cancer and A498 from renal cell cancer. THP-1 monocytic cells are leukaemia derived 
and HeLa cells are from a patient with cervical cancer. TERT-NHUC cell line is 
immortalized with human telomerase reverse transcriptase (hTERT). They resemble 
normal bladder epithelial cells to high degree (Chapman, Hurst et al. 2006). Normal 
human primary mesangial cells (NHMC) used in paper I and II and normal human 
primary bladder epithelial cells (HBEP) in paper IV were both from commercial 
vendors. 5637, A498, THP-1 and HeLa cells were grown in medium recommended 
from ATCC. TERT-NHUC and normal human bladder cells were grown in serum-free 
conditions. NHMC was cultured in NHMC medium (paper I) or RPMI supplemented 
with insulin-transferrin-selenium and FBS (paper I and II). TERT-NHUC requires a 
modified polystyrene surface for optimal growth and were therefore grown in BD 
Primaria treated flasks and multi-well plates.  
 
For the vitamin D studies, all cell experiments were kept away from direct light since 
UV-light rapidly degrades vitamin D compounds (Lebwohl, Quijije et al. 2003). 
Furthermore, instead of normal FBS, charcoal-treated FBS was used to remove 
liposoluble hormones, which may interfere with the biochemical reactions (Cao, West 
et al. 2009).  
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6.3.2.1 Cell treatment and infections 
 
In paper I and II, A498 and NHMC were grown to form a confluent layer while THP-1 
cells in paper II were seeded 106 cells per well. Infections were carried out in serum-
free medium with E. coli CFT073 in the presence of gentamycin 40 µg/mL to prevent 
bacterial overgrowth and decreased cell viability. Cells incubated with medium only 
served as controls. In paper III, T24 bladder cells and renal A498 cells were grown to 
confluency and then infected with CP9cnf1 or CP9lacZ. Cell supernatants were assayed 
for IL-8 and TIMP-1. In paper IV, confluent T24, 5637, TERT-HNUC and HBEP cells 
were treated with 25D3 or 1,25D3 and in selected experiments infected with E. coli 
CFT073 107. 
 
6.3.2.2 Antibacterial assay 
 
To test the antibacterial effect induced by vitamin D treatment of urinary bladder cells, 
T24, 5637 and TERT-NHUC cells were seeded in 6-well plates until nearly confluent. 
1,25D3 or vehicle (ethanol) was added for 48 hours in a thin layer of medium. Bacteria 
were then incubated in the conditioned medium for 90 minutes and the suspension was 
plated on blood agar plates for bacterial count. 
 
6.3.2.3 Cell viability testing 
 
For different treatment and infections, cell viability testing was done using tryptan blue 
staining or the MTT method. Tryptan blue staining was performed in cell suspension 
with tryptan blue reagent and assessed under light microscope. Dead cells take up the 
tryptan blue and are stained blue. Measurement with MTT method was performed after 
cell treatment or infection. Medium was aspirated and MTT solution was added. After 
incubation for one hour the MTT solution was removed and the cells were solubilised 
in DMSO. Absorbance at 540 nm was measured in plate reader (Mosmann 1983).  
 
 
6.3.3 PCR 
 
Total RNA extraction was performed using phenol–chloroform technique in paper I 
and II and with spin column-based technique in paper IV. cDNA was synthesized and 
polymerase chain reaction (PCR) was performed to multiply the targets of interest. In 
paper I, the traditional mode of PCR was used where the specific DNA is amplified 
after which it is separated in a gel and DNA is stained with ethidium bromide to 
confirm the amplicon size (Paper I). For paper IV, real-time PCR with fluorescent 
probes was used. In order to determine changes in mRNA due to specific stimuli, the 
sample was normalized to a housekeeping gene. We used GAPDH (Paper I and II) for 
conventional PCR and 18s (paper IV) for real-time PCR. Changes in mRNA expression 
were calculated by measuring light intensity in the gel (Paper I) or by the 2−ΔΔCT method 
for real-time PCR (Paper IV) (Schmittgen and Livak 2008).  
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6.3.4 ELISA 
 
Urine levels of MMP-9, TIMP-1 and IL-8 as well as mouse MIP-2, MCP-1 and 
RANTES in kidney homogenates were measured using ELISA. MMP-9 in kidney 
homogenates was analyzed with a mouse MMP-9 activity assay. An antibody-based 
chemiluminescence assay was used for total serum 25D3 analyses. Urinary creatinine 
levels were detected using Jaffes method and all human urine protein levels were 
expressed as protein/creatinine ratios. 
 
6.3.5 Histopathology and immunohistochemistry  
 
Histopathology was examined by staining sections of kidney tissue with haematoxylin 
and eosin. The inflammatory changes in mouse kidneys were summed following a 
semi-quantitative blinded scoring system. Immunohistochemistry for MMP-9 and 
TIMP-1 was performed in paper II. Following deparaffinization, rehydration, antigen 
retrieval and blocking, sections were incubated with primary anti-MMP-9 or anti-
TIMP-1 antibodies. A goat anti-rabbit biotinylated secondary antibody was used and 
avidin/biotin complex was formed. Finally, nuclei were stained with DAB and 
sections were mounted in mounting medium.  
 
In paper IV, urinary bladder biopsies were immediately placed in cell culture medium 
and infected with E. coli in a test tube for 90 minutes. After infection, biopsies were 
fixed for immunohistochemistry or processed for RNA extraction (see PCR section).  
 
Fluorescence immunohistochemistry was used to detect cathelicidin, VDR, CYP27B1 
and CYP24A1 in bladder tissue and in bladder cells in culture. Following 
deparaffinization, rehydration and antigen retrieval, blocking with serum and signal 
enhancer, primary anti-cathelicidin, anti-VDR, anti-CYP27B1 and anti-CYP24A1 were 
used with matching secondary AlexaFluor antibodies. Nuclei were stained with DAPI 
and sections were mounted in mounting medium. Cells cultured on cover slips were 
stained in a similar way except for antigen retrieval. Confocal microscopy was 
performed on a Leica SP5 system. Fluorescence intensity was quantified using the 
ImageJ image processing software (Abramoff, Magelhaes et al. 2004). 
 
6.3.6 In situ hybridization 
 
In situ hybridization was used to localize MIP-2, RANTES and MCP-1 mRNA in 
kidney sections of mice with acute pyelonephritis in paper II. Synthetic 
oligonucleotide probes were labelled using 35S dATP. A mixture of two to three 
different probes was used and controls were obtained by parallel hybridization of 
adjacent sections with the 35S-labelled sense probe for each chemokine. Emulsion 
autoradiography was performed and cells expressing more than 15 grains over the 
cytoplasm were counted by dark field microscopy at 100x magnification. Accuracy 
was checked at higher magnification and light microscopy. The tissue section areas 
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were measured by graded mesh and results were expressed as numbers of mRNA 
expressing cells per 100mm2 tissue section. 
 
6.3.7 Flow cytometry 
 
Flow cytometry measures protein on a single cell level, thus making it possible to find 
out how a cell population is distributed with regards to the presence of the peptide or 
protein of interest. We used flow cytometry in paper IV to measure intracellular 
cathelicidin in vitamin D treated and untreated urinary bladder cells. Since they are 
adherent epithelial cells they were first trypsinized in low-concentration trypsin. Cells 
were simultaneously fixed and permeabilized and then labelled with a primary anti-
cathelicidin monoclonal antibody and a secondary Alexa Fluor antibody. Cells were 
analysed on a Becton Dickenson FACScalibur™.  
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7 RESULTS  
 
7.1  CHEMOKINE RESPONSE IN ACUTE PYELONEPHRITIS (PAPER I) 
 
Pyelonephritis is a severe bacterial infection involving inflammation of the renal tissue, 
which may lead to renal scarring if not treated promptly. Inflammatory mediators such 
as cytokines and chemokines elicited upon bacterial infection are thought to induce the 
transition from acute infection to renal scarring. In the first paper, we studied the 
chemokine response in E. coli-induced pyelonephritis in normal and IL-lβ-deficient 
mice. Overall inflammatory changes were more pronounced and more often found in 
IL-1β deficient mice as compared to wild-type mice. In addition, they were more likely 
to have extensive destructive inflammation with large numbers of neutrophils and renal 
cortical abscesses. It is well known that IL-8 is important for the pathogenesis of UTI 
but we show here for the first time that RANTES and MCP-1 are also produced. This 
was seen both in mice with pyelonephritis and in human kidney cells infected with the 
same uropathogenic E. coli strain. IL-1β deficient mice produced more MIP-2 upon 
infection compared to wild-type mice. In summary, in addition to IL-8/MIP-2, the CC 
chemokines MCP-1 and RANTES are produced during experimental pyelonephritis 
and IL-1β deficiency promotes renal inflammation after pyelonephritis.  
 
7.2 MMP-1 AND TIMP-1 IN ACUTE PYELONEPHRITIS (PAPER II) 
  
For chemokines to be activated and for neutrophils to infiltrate the area of infection, the 
proteolytic activities of matrix metalloproteinases (MMPs) are important (Page-
McCaw, Ewald et al. 2007). In paper II, we sought to elucidate the role of MMP-9 and 
its inhibitor TIMP-1 in pyelonephritis and renal scarring in children and in an 
experimental mouse model of pyelonephritis. In children with acute pyelonephritis, 
urine levels of MMP-9 and TIMP-1 were significantly higher compared to 6-week 
follow-ups and to samples from children with non-renal fever. In accordance, TIMP-1 
was expressed in response to E. coli infection in human renal cells. We further 
demonstrated that TIMP-1 levels in children correlated to renal scarring as 
demonstrated by DMSA scan. In children with urinary TIMP-1 levels higher than 
MMP-9, more severe changes were observed in acute and follow-up DMSA scan. 
MMP-9 seemed to be produced mainly in leukocytes whereas TIMP-1 was seen both 
in leukocytes and in renal epithelial cells. Thus, MMP-9 and TIMP-1 are produced as 
a result of ascending E. coli infection in the urinary tract. TIMP-1 rather than MMP-9 
seems to be involved in the process leading to renal scaring following pyelonephritis 
in children and may therefore be used as a marker for risk of developing scarring after 
acute pyelonephritis. 
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7.3 CNF1 AND ITS IMPORTANCE IN URINARY TRACT INFECTION 
(PAPER III) 
 
The host response to E. coli pyelonephritis was studied in papers I and II and implied 
the role of chemokines, cytokines and the MMP inhibitor TIMP-1. In the third paper, 
we wanted to describe the contribution of bacterial virulence factors to the immune 
response and persistence in the urinary tract. While E. coli P fimbriae have been shown 
to induce inflammation in bladder and kidney (Wullt 2003), the role of bacterial toxins 
is not yet clear. Because of contradictory results regarding the effect of the toxin CNF1 
in UTI mouse models, we decided to take a more clinical approach. We hypothesised 
that patients infected with CNF1-positive strains would have higher inflammatory 
markers in the urine and that CNF1-positive strains would be overrepresented in 
children with recurrent UTIs as a result of increased persistence in the urinary tract. By 
infecting uroepithelial and kidney cells with CNF1-negative or CNF1-positive bacteria, 
we could investigate the effect on adhesion and invasion into cells. No difference was 
found when only live bacteria were used. When the cells were pre-treated with 
sonicated bacteria and then infected with live bacteria, CNF1-positive bacteria attached 
more efficiently than CNF1 negative bacteria. Since persistence in the urinary tract is 
an important feature of the pathogenesis of UTI, we then correlated CNF1 expression 
to the likelihood of causing recurrent UTI. However, CNF1 frequency did not differ 
between children with sporadic or recurrent UTI. Although CNF1-expressing E. coli 
and purified CNF1 toxin increased IL-8 in uroepithelial cells and monocytes, children 
and adults with UTI showed no correlation between CNF1 expression and IL-8 levels.  
 
 
Since TIMP-1 levels correlated to renal scarring in our previous study, we investigated 
the effect of CNF1 on TIMP-1 expression as well. A rapid increase was observed in 
kidney epithelial cells, but not in bladder cells. Our results suggest that although CNF1 
induces IL-8 and TIMP-1 in uroepithelial and renal epithelial cells in culture, it seems 
more likely that other virulence factors contribute more to inflammation and 
persistence in the urinary tract in vivo. 
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7.4 VITAMIN D INDUCTION OF CATHELICIDIN IN THE HUMAN URINARY 
BLADDER (PAPER IV) 
 
After studying the inflammatory response in acute pyelonephritis we were interested in 
finding out how to increase endogenous defence mechanisms in the urinary tract. Our 
group previously showed that the antimicrobial peptide cathelicidin protects the urinary 
tract from infection (Chromek, Slamova et al. 2006). Since it was also shown that 
vitamin D could induce cathelicidin in monocytes (Liu, Stenger et al. 2006), we 
investigated if vitamin D would have a similar effect in the urinary bladder. 
Postmenopausal women were supplemented with cholecalciferol (vitamin D3) for 12 
weeks. Serum-25D3 increased by 41% without affecting calcium, phosphate, 
parathyroid hormone or serum cathelicidin. Before and after the three months of 
vitamin D3 supplementation, biopsies were taken from the urinary bladder mucosa. 
Cathelicidin increased significantly in E. coli infected biopsies after the 
supplementation period compared to before. In addition, several different bladder cell 
lines and primary bladder cell were treated with vitamin D. Induction of cathelicidin 
was seen on both mRNA and protein level. 
 
 
Figure 5. Vitamin D induction of cathelicidin.  
Bladder epithelial cells were treated with 1,25D3 or 25D3. Gene expression of CAMP 
(A) as well as cathelicidin peptide (B) increased. Uropathogenic E. coli (UPEC) 
increased the cathelicidin when combined with vitamin D treatment. 
 
To be functional, 25D3 needs to be converted to 1,25D3. We showed that the 
converting enzyme, CYP27B1 is present and active in the urinary bladder. Increased 
cathelicidin was seen on mRNA and protein levels after 25D3 or 1,25D3 treatment and 
with additional increase if the cells were infected with E. coli. 
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We also show that uroepithelial cells facilitate intracellular killing of E. coli and that 
bacteria and cathelicidin co-localised in the bladder cells. With these findings, we 
further investigated the functional role of vitamin D-induced cathelicidin in urinary 
tract cells. After treating uroepithelial cells with vitamin D or vector only, we incubated 
the conditioned medium with E. coli. Significantly more bacteria recovered from the 
vector-treated medium compared to the vitamin D treated. The result was similar when 
we lysed the cells to evaluate intracellular antibacterial properties. Finally, a 
neutralizing antibody against cathelicidin blocked the antibacterial effect in vitamin D 
treated medium (Figure 5).  
 
These results show that the bladder is equipped with the enzymes and receptors 
necessary for vitamin D activation and that vitamin D treatment increases the 
antibacterial effect by induction of the antimicrobial peptide cathelicidin. 
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Figure 6. Antibacterial effect of vitamin D treated bladder cells.  
Bladder epithelial cells (TERT-NHUC) were treated with 1,25D3. An anti-cathelicidin 
neutralizing antibody abrogated the antibacterial effect of the resulting conditioned 
medium against uropathogenic E. coli.  
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8 DISCUSSION 
 
Urinary tract infection remains one of the most common bacterial infections despite 
widely accessible diagnostic aids, antibiotics and increased knowledge about its 
pathogenesis. The first line of defence in the lower urinary tract will in most cases 
succeed in preventing bacterial attachment and establishment. However, sometimes, 
and more often in certain risk groups, bacteria will establish themselves in the urinary 
tract to cause infection. Less commonly, bacteria spread to the upper urinary tract 
causing pyelonephritis. Children and women with recurrent UTI are often prescribed 
antibiotics repeatedly or as prophylaxis for longer periods of time. The problem of 
bacterial resistance to antibiotics used in UTI is increasing at high speed and new 
treatment strategies are therefore needed. In order to be able to therapeutically 
intervene in the host-pathogen interaction in the urinary tract, better understanding of 
the pathophysiology is needed. In this thesis we studied the immune response in human 
UTI as well as in a mouse model and cell lines. We describe new findings about 
chemokine production and proteinase release in pyelonephritis in vitro as well as in 
vivo. We also present a new way of increasing the endogenous antimicrobial defence in 
the urinary bladder.  
 
In paper I, we investigated the role of IL-1β in the pathogenesis of pyelonephritis and 
renal scarring as well as the expression of the CXC chemokine IL-8 and the CC 
chemokines MCP-1 and RANTES. Since IL-lβ genotype influences the severity of 
meningococcal disease (Read, Camp et al. 2000) and IL-lβ deficiency is associated 
with delayed clearance of Chlamydia in salpingitis in mice (Prantner, Darville et al. 
2009), we were interested in its role in acute pyelonephritis. Accordingly, the 
histological kidney changes suggested increased inflammation and renal scarring in the 
IL-lβ-deficient mice. However, the total bacterial count in the kidney did not differ in 
the IL-lβ- deficient and wild type mice, implying that the histological differences rather 
reflect an altered immune response to bacteria. Indeed, the higher MIP-2 levels found 
in IL-lβ-deficient mice support this. In vitro on the other hand, IL-lβ treatment led to 
increased cytokines in renal cells, something that is supported by a recent gene array 
study (Thorburn, Kolesar et al. 2009). This discrepancy in the animal model and in cell 
culture is probably a result of complex cross talk between different cells in vivo.  
 
The high MIP-2 levels found in IL-lβ-deficient mice may provide an explanation for 
the increased renal scarring seen in IL-lβ-deficient mice. With more neutrophils 
infiltrating the tissue more cytotoxic compounds are subsequently released. In fact, 
neutralizing MIP-2 has successfully decreased neutrophil influx and tissue damage in 
haemolytic uremic syndrome (Roche, Keepers et al. 2007) as well as renal 
ischemia/reperfusion injury (Miura, Fu et al. 2001). In pyelonephritis on the other hand, 
MIP-2 seems to have dual functions. Initially, it is responsible for attracting neutrophils 
from the circulation; next, MIP-2 directs neutrophils across the epithelium and into the 
urine. At this latter stage, blocking MIP-2 prevents this transmigration and leads to 
entrapment of neutrophils in the sub-epithelial tissue (Hang, Haraoka et al. 1999).  
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With the extensive histo-pathological changes seen in the IL-lβ-deficient mice, they are 
more likely to have a systemic inflammation. Recently, it was demonstrated that 
systemic IL-lβ can induce endogenous cortisol increase (Tkachenko, Jaaskelainen et al. 
2011; Vukelic, Stojadinovic et al. 2011) and in LPS-challenged mice, serum cortisol 
elevation was impaired in IL-1α/ IL-lβ-deficient mice (Oguri, Motegi et al. 2002). IL-
lβ-deficiency in our study may therefore predispose to increased proinflammatory 
signalling through impaired cortisol production. Children with acute pyelonephritis 
treated with cortisone have earlier normalization of DMSA scan abnormalities (Huang, 
Chen et al. 2011), highlighting the importance of the cortisol system in renal 
inflammation.  
 
In comparison to IL-8, not much attention has been given to the CC chemokines in 
UTI. Since MCP-1 and RANTES have both been associated with the development of 
interstitial fibrosis in kidneys (Lloyd, Minto et al. 1997; Schneider, Panzer et al. 1999) 
they are also of interest to study in post-infectious renal scarring. Bacteria and IL-1β 
induced IL-8/MIP-2, RANTES and MCP-1 in vitro as well as in vivo. However, in IL-
lβ-deficient mice where profound MIP-2 accumulation was observed, there was no 
RANTES and MCP-1 increase. These findings point toward individual differences in 
activation of different chemokines, something that may prove important in attempts to 
modulate their actions.  In parallel with our study, Tsuboi et al found similar results in 
mouse renal epithelial cells treated with LPS (Tsuboi, Yoshikai et al. 2002). 
Interestingly, they showed that the RANTES increase, unlike MCP-1, was dependent 
on de novo protein synthesis, which could explain the delay we saw in RANTES 
induction after treatment with E. coli or IL-1β. Unlike Tsuboi et al, who studied LPS-
stimulated mouse renal cells, we used whole uropathogenic E. coli to mimic the natural 
situation when infecting human cells and mice. These differences aside, distinct 
concordance is found in the two studies, emphasizing the similarities of activation of 
cells of different origin in response to bacteria or bacterial products.  
 
For chemokines to be activated and to recruit neutrophils, and for neutrophils to travel 
through tissue to infiltrate the area of infection, the matrix metalloproteinases are 
important (Page-McCaw, Ewald et al. 2007). In paper II, we found that MMP-9 and 
TIMP-1 increased in the urine of children with UTI and we localised the production to 
infiltrating leucocytes and renal epithelial cells by using our mouse model of UTI. 
Interestingly, in children, elevated TIMP-1 but not MMP-9, was associated with renal 
scaring. This suggests that TIMP-1 rather than MMP-9 contributes to the pathogenesis 
of renal scarring following acute pyelonephritis. These findings were further 
supported in later studies demonstrating that TIMP-1 may cause entrapment of 
neutrophils and destruction of renal parenchyma (Chromek, Tullus et al. 2004).  
 
It is also well known that MMP-9 can activate important mediators in the early innate 
immune cascade. Hence, inhibiting MMP-9 may affect this process and thereby 
accelerating the infectious process. Following our study, several others have showed 
increased MMP-9 and TIMP-1 in bacterial infection such as meningitis (Tsai, Shi et al. 
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2011), septicaemia (Lauhio, Hastbacka et al. 2011) and in S. pneumoniae infection in 
the lung (Hong, Greenlee et al. 2011). In the later study, MMP-9 was found to be 
important in the early defence against bacteria by cleavage of IL-17, which is required 
to avoid excessive accumulation of neutrophils in the lung. MMP-9 also increased 
reactive oxygen mediated bacterial killing by neutrophils. Furthermore, MMP-9 can 
activate TGF-β, which seems to be protective against post-infectious renal scaring 
(Farmaki, Papachristou et al. 2005) but also to have pro-fibrotic properties in 
obstructive kidney diseases (Duymelinck, Dauwe et al. 2000). TIMP-1, which we could 
correlate to renal scarring, has been shown to be down-regulated by IL-1β in renal 
proximal tubular cells (Nee, McMorrow et al. 2004). Hence, in mice lacking IL-1β, one 
would expect TIMP-1 levels to be higher, leading to an increased risk of renal scarring. 
 
 
 
Figure 7. Pathogenesis of renal scarring. 
E. coli (green) attach to the epithelial cell (1) resulting in cytokine and chemokine  
secretion (2). The chemotactic gradient of MIP-2 directs the neutrophils from the 
circulation (3) into the tissue where an excess of reactive oxygen species are formed 
(oxidative burst) and cytotoxic granular products released (degranulation). 
Neutrophils further transverse the epithelium into the urine (4). An increased 
production of TIMP-1 leads to imbalance between MMP-9 and TIMP-1, which 
contributes to fibrosis development as a result of increased collagen accumulation (5).  
 
In studies I and II, we examined the tissue inflammation in acute pyelonephritis and 
renal scarring. Renal scarring is dependent on the degree of inflammation as found in 
many studies where high acute-phase protein and cytokines levels predict renal scarring 
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(Tullus, Fituri et al. 1994; Bressan, Andreola et al. 2009). Since TIMP-1 correlated 
with renal scarring, we wanted to study if specific bacterial factors contributed to the 
initial inflammation.  
 
P-fimbriae and type-1 fimbriae are well-studied bacterial factors in the uropathogenic 
E. coli. P-fimbriae initiate inflammation in the urinary tract (Linder, Engberg et al. 
1991; Bergsten, Samuelsson et al. 2004). Although type-1 fimbriae facilitate 
attachment (Zhou, Mo et al. 2001), invasion (Martinez, Mulvey et al. 2000) and the 
formation of intracellular bacterial communities (Wright, Seed et al. 2007) in the 
urothelium, inflammation in the bladder in vivo has not been demonstrated (Bergsten, 
Wullt et al. 2007). This appears to be logical since half of ABU strains express type-1 
fimbriae (Roos, Nielsen et al. 2006) and should by definition not elicit inflammation.   
 
Bacterial toxins like hemolysin and CNF1 and their role in UTI are less well 
understood. Although hemolysin was shown to induce calcium oscillation-induced 
cytokine release in vitro (Uhlen, Laestadius et al. 2000), it was not associated with 
acute inflammation in UTI (Connell, de Man et al. 1993). CNF1 seems to be important 
for UTI pathogenesis since it is expressed in a majority of UTI strains (Brauner, 
Katouli et al. 1990). We demonstrate that CNF1 promotes bacterial attachment and 
invasion to uroepithelial cells and that it can induce an inflammatory response with IL-
8 and TIMP-1 production. However, as we studied the urine of children and adults with 
UTI, no correlation between CNF1 expression and inflammatory response or recurrent 
infections were found. Thus, although CNF1 contributes in vitro, it seems to be less 
important in vivo.  
 
Previous studies in mice have shown conflicting results regarding immune response to 
CNF1 in the urinary tract. Johnson and colleagues demonstrated that CNF1 does not 
contribute to colonization, persistence or inflammation in the murine urinary tract 
(Johnson, Drachenberg et al. 2000) or damage to human bladder cells in vitro (Island, 
Cui et al. 1998). Others on the contrary, found that CNF1-positive strains caused 
deeper infection in murine UTI (Rippere-Lampe, O'Brien et al. 2001) and increased 
cytotoxicity in bladder cells (Mills, Meysick et al. 2000). Real et al. used a similar, 
clinical approach in a study parallel to ours. They showed that patients with 
haemorrhagic UTI more often were infected with E. coli carrying the cnf1 gene and 
that MCP-1 and IL-8 were significantly higher in the urine of patients with cnf1 gene 
positive E. coli (Real, Munro et al. 2007). The main differences compared to our study 
are that we made a phenotypic rather than genotypic estimate of CNF1 expression and 
that we included the outcome of recurrences as a measurement of persistence in the 
urinary tract.  
 
One reason for CNF1 not to be associated with more inflammation or recurrent UTIs in 
our study could be that CNF1 also induces apoptosis (Mills, Meysick et al. 2000). 
Apoptosis in the bladder leads to shedding of the superficial uroepithelial cells, thus 
clearance of bacteria attached and invaded into the shedded cells. This is a beneficial 
host response although there is a risk that shedding will expose underlying cells to 
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infection. In the kidneys, the single-layered epithelium is vulnerable to bacterial toxins 
and apoptosis is not a protective response. Therefore, if the bacteria reach the kidneys, 
CNF1 probably induce kidney tissue damage. Another reason could be the stronger IL-
8 response with CNF1 leading to efficient clearance of the bacteria by infiltrating 
neutrophils. If the host fails to induce IL-8, or the mouse equivalent MIP-2, the 
bacterial burden increases (Haraoka, Hang et al. 1999).  
 
There is still uncertainty to what extent CNF1 contributes to the immune response in 
UTI in vivo. We were not able to show any adverse consequences correlated to E. coli 
equipped with CNF1. There are problems however when interpreting studies like this. 
Since the cnf1 gene almost always is co-expressed with hly it is difficult to evaluate the 
impact of cnf1 versus hly. An E. coli knockout strain specifically lacking cnf1 is 
therefore a very useful tool. We and others have used this approach with conflicting 
results as discussed above. The strengths in our study are the clinical outcome and that 
both live bacteria and purified CNF1 toxin were used. 
 
Although UTIs are common, it is surprising how well the urinary tract can withstand 
bacterial infection taking into account the anatomical location. It is also well known 
that bacteria frequently enter the urinary tract without causing symptoms of UTI. 
Several factors are involved in keeping the urine free from bacteria or preventing the 
bacteria from invading the uroepithelium. Apart from the mechanical forces of the 
urine flow and the neutralizing secreted proteins, antimicrobial peptides are produced 
both in the kidney and in the bladder. Human beta defensin-1 is constitutively produced 
mainly in the renal epithelial cells and cathelicidin in the kidney and in the bladder. 
Both possess antimicrobial activity against E. coli (Valore, Park et al. 1998; Chromek, 
Slamova et al. 2006; Hertting, Holm et al. 2010). Cathelicidin seems to be produced in 
low concentrations constitutively but is rapidly released as bacteria come in contact 
with the epithelium (Chromek, Slamova et al. 2006).  
 
Vitamin D induces cathelicidin in skin (Peric, Koglin et al. 2009), respiratory 
epithelium (Yim, Dhawan et al. 2007), white blood cells (Wang, Nestel et al. 2004) and 
placenta (Liu, Kaplan et al. 2009) and in study IV we show for the first time production 
in the urinary bladder. Postmenopausal women were treated with vitamin D for 12 
weeks. Cathelicidin expression increased in E. coli-infected bladder biopsies taken after 
vitamin D supplementation. Vitamin D alone was not enough to cause cathelicidin 
increase in the biopsies. This is in contrast to what we found in urinary bladder cells in 
culture and may merely reflect differences in intracellular vitamin D levels in vivo 
compared to in vitro. Prolonged elevated levels of cathelicidin in the urinary bladder 
may cause inflammation (Oottamasathien, Jia et al. 2011). Therefore, activation of 
cathelicidin only when bacteria are present may be beneficial to the host.   
 
Both 25D3 and 1,25D3 increased cathelicidin in cultured cells. Similarly, respiratory 
epithelial cells reacted with increased cathelicidin production after 25D3 and 1,25D3 
treatment (Hansdottir, Monick et al. 2008). Monocytes however, seem not to induce 
cathelicidin in response to 25D3 unless also treated with a TLR ligand (Liu, Stenger et 
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al. 2006). 1,25D3 on the other hand, activated cathelicidin also in the absence of 
additional stimuli. 25D3 is inactive unless converted to 1,25D3, which means that the 
difference between monocytes and epithelial cells seems to be the conversion of 25D3 
to 1,25D3. We found that the converting enzyme CYP27B1 is present in the human 
bladder and that it functionally converts 25D3 to 1,25D3. This is important since it 
means that the production of active vitamin D can occur locally and that this locally 
converted vitamin D leads to production of cathelicidin.  
 
With these findings, we have introduced a potentially new concept for the treatment of 
UTIs. By supplementing with vitamin D, the preparedness of the epithelium for 
bacterial invasion is increased through the production of cathelicidin. Indeed, vitamin D 
status influences the risk of obtaining infectious diseases. People with low levels of 
vitamin D run increased risk of acquiring tuberculosis (Gibney, MacGregor et al. 2008; 
Hansdottir, Monick et al. 2008; Williams, Williams et al. 2008) and cord blood vitamin 
D deficiency is associated with respiratory syncytial virus bronchiolitis in the first year 
of life (Belderbos, Houben et al. 2011). In both of these infections, at least in vitro, 
cathelicidin has been shown to be of importance (Hansdottir, Monick et al. 2008; 
Sonawane, Santos et al. 2011). Although it remains to be shown weather vitamin D 
supplementation can prevent UTI in clinical studies, we here show that vitamin D 
functionally upregulates cathelicidin in the urinary bladder.  
 
 
 
 
Figure 8. Schematic figure of the vitamin D supplemented (left) and vitamin D 
deficient (right) state in the urinary bladder.  
Insufficient vitamin D levels lead to lower substrate for the converting enzyme 
CYP27B1. In turn, less of the active 1,25D3 is produced and less cathelicidin can be 
produced. This may lead to increased susceptibility to E. coli infection.  
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In postmenopausal women, the conversion of 25D3 to 1,25 D3 depends on the substrate 
concentration (Rejnmark, Vestergaard et al. 2008), which emphasizes the need for 
sufficient levels of serum 25D3. Skin exposure to UVB light is by far the most efficient 
way of increasing serum levels and compared with ingested vitamin D, skin derived 
vitamin D may last at least twice as long in the blood (Haddad, Matsuoka et al. 1993). 
Lowest serum 25D3 are found in the end of winter worldwide (Holick 2011) but with 
the limited amount of sunlight at the northern latitude, there is an increased risk of 
vitamin D deficiency here. Under these circumstances, it is important with a sufficient 
daily intake of vitamin D. However, food sources of vitamin D are limited (Holick 
2006). Fatty fish such as salmon, tuna and mackerel are exceptions and smaller 
amounts of vitamin D levels are also found in egg yolk and cheese. Therefore, 
supplementation of dairy products and infant formula with vitamin D is a common 
practice. However, recent recommendations from leading researchers in the field 
suggest levels far higher than what could be achieved from the diet alone. This year, the 
Institute of Medicine of the National Academies, USA increased the recommended 
daily intake of vitamin D to 600 IU (Ross, Manson et al. 2011), which reflects the 
growing belief that higher daily doses than previously recommended are needed. 
Recent data from the United States suggest that 90% of women older than 70 years 
did not meet the recommended daily intake of vitamin D (Ross 2011) . The Swedish 
National Food Agency recommends 400 IU for children under 2 years and 300 IU for 
children above two years and for adults (Becker W 2005) and a tolerable upper intake 
level of 2000 IU per day. 
 
Table 2. Recommended dietary allowance of vitamin D from American and 
Swedish guidelines 
                                
Age 
(years) 
IOM 1997 
(IU/day) 
IOM 2011 
(IU/day) 
SWE 
(IU/day) 
0-1  400 400* 
1-50 200  600 300 
50-70 400 600 300 
>70 600 800 300 
Pregnancy & 
Lactation 
 600 400 
 
IOM = Institute of Medicine of National Academies (USA)  
SWE=Swedish recommendations.  *0-2 years. 
 
25D3 can be given in high doses without adverse events as seen in a recent study where 
pregnant and nursing women were given up to 6000 IU daily (Hollis, Johnson et al. 
2011) and as expected, with 2000 IU daily we found no effect on calcium or 
cathelicidin in serum. 1,25D3 however, should be used with caution due to the risk of 
hypercalcaemia. It is mainly used as a therapeutic agent for treating vitamin D 
deficiency if the converting activity is severely compromised as in chronic kidney 
disease (Zehnder, Quinkler et al. 2008). Because of its calcaemic properties, 
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structurally modified analogues have been developed. Although these have been 
subjected to trials in patients with chronic kidney disease, no clinical trials on 
antimicrobial peptide induction have been published. Our data support that increasing 
serum vitamin D levels also increases the antimicrobial properties of the urinary tract. 
Vitamin D insufficiency should be considered in patients with recurrent urinary tract 
infections and, if needed, appropriate supplementation should be started.  
 
Taking advantage of the immune response both for diagnostic and therapeutic purposes 
is one of the great challenges for researchers in the field of infectious diseases. In the 
future, diagnostic tools may include a number of pathogen and host response markers, 
which may aid the clinician to the right diagnosis and to find the patients at risk of 
severe disease or renal scarring.  In this thesis, TIMP-1 is proposed as a marker for 
renal scarring and perhaps also to distinguish upper from lower UTI, a difficult but 
important task especially in young children (Pecile, Miorin et al. 2004). Larger clinical 
studies to evaluate TIMP-1 and other inflammatory markers in UTI could prove 
important. 
 
A major obstacle for scientists today is the increasingly problematic situation with 
bacterial resistance against conventional antibiotics. As indicated by the WHO and 
because UTI is such a common infection, this may very well constitute an impending 
public health crisis. New antibiotics and altogether new treatment strategies are 
therefore needed. Although the number of antibiotics in clinical trials is now increasing 
for the first time in 30 years, the pipeline of antibiotics with entirely new mechanisms 
of action is still close to empty (Payne, Gwynn et al. 2007). Therefore, antimicrobial 
peptides constitute a promising new treatment group and little resistance has been 
observed. However, the nature of these peptides makes them difficult to administer and 
expensive to synthesize. There are also adverse effects of AMPs reported like bladder 
inflammation (Oottamasathien, Jia et al. 2011) and tumour progression (Coffelt, Marini 
et al. 2009). Based on the findings in this thesis, we believe that therapeutic methods to 
induce endogenous AMPs are the most promising way forward. Patients suffering from 
recurrent urinary tract infections are especially well suited for clinical trials of vitamin 
D treatment.  
 
We also show intracellular killing taking place in the bladder mucosa. This is important 
since UPECs enter the urothelial cells to form intracellular bacterial communities as a 
strategy to escape the immune response and antibiotics. This has entirely changed the 
old concept of uropathogenic E. coli being an obligate extracellular pathogen and 
therefore, new pharmacological treatment must have the capacity of killing bacteria 
also intracellularly. Upon vitamin D treatment of bladder epithelial cells in vitro, we 
showed that the antibacterial effect increased both extracellularly and intracellularly, 
which may indicate that vitamin D is also efficient against the intracellular niche of 
bacteria. Randomized, double-blind, placebo-controlled studies are of importance in 
order to evaluate the role of vitamin D in UTI and to clinically evaluate the findings 
presented here.	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9 FUTURE PERSPECTIVES 
Modern medicine faces enormous challenges with an increasing population and more 
expensive and advanced treatments.  Therefore, the future of medicine is dependent on 
finding individuals at risk so that disease can be avoided. Individual assessment is also 
important because it enables treatment to be adjusted around the specific set of 
biological characteristics for that patient. Apart from the potential clinical benefit of our 
findings already discussed, future perspectives include increased awareness of genetic 
predisposition to UTI and tailored treatment. Genetic variation in genes that regulate 
the innate immune response in UTI may influence the susceptibility to infection. In the 
activation of vitamin D, the converting enzyme CYP27B1, the 1,25D3 catabolic 
enzyme CYP24A1 and the VDR have been associated with gene polymorphism in 
different studies ranging from diabetes, cancer, neurological disorders but also 
infectious diseases. It would be of great interest to study alterations in the genetic 
vitamin D metabolism pathways of patients with recurrent UTIs. This would provide 
information that could help us identify individuals at risk of recurrent or severe UTI but 
also to provide these patients with prompt and correct evaluation and treatment.  
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10 CONCLUSION 
 
From the results presented in this thesis the following specific conclusions were drawn: 
 
I. The chemokines MIP-2, MCP-1 and RANTES are expressed in a mouse 
model of acute E. coli pyelonephritis. IL-1β deficient mice showed an 
increased MIP-2 production and more severe renal scarring than wild 
type mice.  
 
II. MMP-9 and TIMP-1 are produced in acute E. coli pyelonephritis in 
children. TIMP-1 correlates with renal scarring following acute 
pyelonephritis.  
 
III. In vitro, CNF1 contributes to the inflammatory response in urinary 
bladder cells. In vivo however, the presence of CNF1 seems to be of 
subordinate importance.  
 
IV.  Vitamin D induces the expression of cathelicidin in E. coli infected 
urinary bladder biopsies of postmenopausal women and in human urinary 
bladder cells, which has an E. coli-cidal effect.  
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